1418-DHA Potentiates Regorafenib and Anti-PD-1

Paper Talk · Aug 11, 2026 · 22m

This research paper explores how KRAS mutations cause resistance to a combination treatment of regorafenib and anti-PD-1 therapy in patients with colorectal cancer liver metastases. The authors identified dihydroartemisinin (DHA), a common anti-malarial drug, as a powerful agent capable of selectively degrading mutant KRAS proteins through the autophagy-lysosome pathway. Through various preclinical models, the study demonstrates that DHA enhances the effectiveness of immunotherapy by restoring interferon responses and promoting a more aggressive immune cell environment within tumors…